Bioscience Biotechnology Research Communications

An International  Peer Reviewed Refereed Open Access Journal

P-ISSN: 0974-6455 E-ISSN: 2321-4007

Bioscience Biotechnology Research Communications

An Open Access International Journal

Ganesh Kumar Jhunjhunwala 1 Rakesh Kumar Jha, 2
and Dhruba Hari Chandi3

1First year MBBS, Datta Meghe Medical College, Nagpur Maharashtra

2Department of Biochemistry Datta Meghe Medical College, Shalinitai Meghe Hospital and Research Centre Nagpur

3Department of Microbiology Jawaharlal Nehru Medical College, Datta Meghe Institute of
Medical Sciences Sawangi (Meghe), Wardha

Corresponding author email: jhaarakesh1993@gmail.com

Article Publishing History

Received: 14/04/2021

Accepted After Revision: 06/06/2021

ABSTRACT:

It’s about year 2019 during the month of November & December corona virus, Severe Acute respiratory syndrome has been reported as transmitting agent for viral infection pneumonia. It out-breaks in city of China, now commonly known as corona virus or (COVID19). The basic knowledge collected about the lethal, pandemic human coronavirus SARS Corona virus (COVID19) is discussed in this article, with a focus on its zoonosis, resistance, and various therapeutic development strategies.

KEYWORDS:

Therapeutics, SARS, MERS, FDA, ORF & COVID-19

Download this article as:

Copy the following to cite this article:


Copy the following to cite this URL: